Medical Condition News RSS Feed - Medical Condition News

Anxiety experienced with false-positive mammogram does not negatively impact woman's well-being

Anxiety experienced with false-positive mammogram does not negatively impact woman's well-being

Dartmouth researchers have found that the anxiety experienced with a false-positive mammogram is temporary and does not negatively impact a woman's overall well-being. Their findings are reported in "Consequences of False-Positive Screening Mammograms," which was published online in the April 21, 2014 JAMA Internal Medicine. [More]

Studies identify 2 genes highly associated with IBD

Inflammatory Bowel Disease (IBD), a group of chronic inflammatory disorders of the intestine that result in painful and debilitating complications, affects over 1.4 million people in the U.S., and while there are treatments to reduce inflammation for patients, there is no cure. [More]

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

Surefire Medical, Inc. announced that a symposium focused on the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial will be held during the European Conference on Interventional Oncology (ECIO) meeting taking place in Berlin, Germany April 23-26. T [More]
Plymouth scientists receive MRC grant to lead new and effective therapies for Parkinson's disease

Plymouth scientists receive MRC grant to lead new and effective therapies for Parkinson's disease

A team of scientists led by researchers at Plymouth University Peninsula Schools of Medicine and Dentistry, has received a grant from the Medical Research Council (MRC) for work which could lead to new and effective therapies for those with Parkinson's Disease. [More]

VHVI implants miniaturized HeartWare HVAD Pump through minimally invasive approach

Sometimes smaller is better. This is especially true of left ventricular assist devices, the mechanically operated heart pumps that are implanted in heart failure patients to bridge them to transplantation. [More]

Avedro receives Canadian approval for KXL II System

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today the Canadian approval for the company's KXL II System. The KXL II System performs a procedure called PiXL (Photorefractive Intrastromal Cross-Linking) which has the potential to deliver non-surgical correction of myopia, and improve cataract surgery outcomes. [More]
Rhenovia Pharma's SMARTT e-Patch project wins award at the French ‘World Innovation Challenge'

Rhenovia Pharma's SMARTT e-Patch project wins award at the French ‘World Innovation Challenge'

Rhenovia Pharma, a biotechnology company specialized in the application of biosimulation to the research and development of new medicinal products, today announces that its SMARTT e-Patch project has won an award at the ‘World Innovation Challenge’; founded by the President of France to identify future champions in the French economy. [More]

Study: Excessive fetal growth increases risk of stillbirth

Researchers from the University of Texas Medical Branch and the Stillbirth Collaborative Research Network have identified a link between stillbirth and either restricted or excessive fetal growth. Findings from the study are online in the April 22 issue of PLOS Medicine. [More]

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Between 10 and 20 percent of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy. [More]
New studies may offer hope for people with migraine

New studies may offer hope for people with migraine

Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014. [More]
NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

​Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. [More]
New FDA-approved device reduces seizures in patients with medication-resistant epilepsy

New FDA-approved device reduces seizures in patients with medication-resistant epilepsy

A recently FDA-approved device has been shown to reduce seizures in patients with medication-resistant epilepsy by as much as 50 percent. When coupled with an innovative electrode placement planning system developed by physicians at Rush, the device facilitated the complete elimination of seizures in nearly half of the implanted Rush patients enrolled in the decade-long clinical trials. [More]
New computational tool identifies undiagnosed illnesses and unknown gene mutations

New computational tool identifies undiagnosed illnesses and unknown gene mutations

A computational tool developed at the University of Utah (U of U) has successfully identified diseases with unknown gene mutations in three separate cases, U of U researchers and their colleagues report in a new study in The American Journal of Human Genetics. [More]

New painkiller, with fewer side-effects, up for FDA approval

The drug, Moxduo, allows patients to take lower doses of other painkillers. Elsewhere, a Food and Drug Administration official talks about another painkiller, Zohydro. [More]

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Bayer HealthCare today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis (NCFB). [More]
Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. [More]

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]

Older parents are more likely to have child with autism spectrum disorder, says study

Older parents are more likely to have a child who develops an autism spectrum disorder (ASD) than are younger parents. A recent study from researchers from the Drexel University School of Public Health in Philadelphia and Karolinska Institute in Sweden provides more insight into how the risk associated with parental age varies between mothers' and fathers' ages, and found that the risk of having a child with both ASD and intellectual disability is larger for older parents. [More]

Cedars-Sinai researchers to receive $8M grant to fund Phase II clinical trial of experimental drug for stroke

​Cedars-Sinai stroke intervention researchers have been informed that the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, will award an $8 million grant to fund a multicenter Phase II clinical trial of an experimental drug for stroke. [More]
OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec to present update of data from Phase 2 melanoma study at ASCO Annual Meeting

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present an update of data from their Phase 2 melanoma study at the American Society of Clinical Oncology's 50th Annual Meeting, taking place May 30-June 3, 2014, at McCormick Place in Chicago, Illinois. [More]